Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

Related Articles by Review for PubMed (Select 17550302)

2.

Industry sponsorship and research outcome.

Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L.

Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033. doi: 10.1002/14651858.MR000033.pub2. Review.

PMID:
23235689
3.
4.
5.

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies.

Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, Als-Nielsen B, Balk E, Gluud C, Gluud L, Ioannidis J, Schulz K, Beynon R, Welton N, Wood L, Moher D, Deeks J, Sterne J.

Health Technol Assess. 2012 Sep;16(35):1-82. Review.

6.

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.

Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD.

JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. Review.

PMID:
21386079
7.

Funding source and the quality of reports of chronic wounds trials: 2004 to 2011.

Hodgson R, Allen R, Broderick E, Bland JM, Dumville JC, Ashby R, Bell-Syer S, Foxlee R, Hall J, Lamb K, Madden M, O'Meara S, Stubbs N, Cullum N.

Trials. 2014 Jan 14;15:19. doi: 10.1186/1745-6215-15-19. Review.

8.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

9.

Characteristics of randomized trials published in Latin America and the Caribbean according to funding source.

Reveiz L, Sangalang S, Glujovsky D, Pinzon CE, Asenjo Lobos C, Cortes M, Cañón M, Bardach A, Bonfill X.

PLoS One. 2013;8(2):e56410. doi: 10.1371/journal.pone.0056410. Epub 2013 Feb 13. Review.

10.

Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review.

Peura PK, Martikainen JA, Purmonen TT, Turunen JH.

Med Decis Making. 2012 Mar-Apr;32(2):237-45. doi: 10.1177/0272989X11403834. Epub 2011 Apr 13. Review.

PMID:
21490308
11.

Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Lexchin J, Bero LA, Djulbegovic B, Clark O.

BMJ. 2003 May 31;326(7400):1167-70. Review.

12.

Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?

Golder S, Loke YK.

Br J Clin Pharmacol. 2008 Dec;66(6):767-73. doi: 10.1111/j.1365-2125.2008.03272.x. Epub 2008 Jul 31. Review.

13.

Industry funding and the reporting quality of large long-term weight loss trials.

Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB.

Int J Obes (Lond). 2008 Oct;32(10):1531-6. doi: 10.1038/ijo.2008.137. Epub 2008 Aug 19. Review.

14.

Bias in clinical intervention research.

Gluud LL.

Am J Epidemiol. 2006 Mar 15;163(6):493-501. Epub 2006 Jan 27. Review.

15.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

16.

When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.

Catalá-López F, Sanfélix-Gimeno G, Ridao M, Peiró S.

PLoS One. 2013 Jul 8;8(7):e69462. doi: 10.1371/journal.pone.0069462. Print 2013. Review.

17.

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.

18.

Financial relationships in economic analyses of targeted therapies in oncology.

Valachis A, Polyzos NP, Nearchou A, Lind P, Mauri D.

J Clin Oncol. 2012 Apr 20;30(12):1316-20. doi: 10.1200/JCO.2011.38.6078. Epub 2012 Mar 19. Review.

PMID:
22430267
19.
20.

Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor.

Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, Scaioli G, De Vito C, Siliquini R, Villari P, Ioannidis JP.

J Clin Epidemiol. 2015 Jul;68(7):811-820. doi: 10.1016/j.jclinepi.2014.12.016. Epub 2015 Feb 7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk